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Abstract: 
To date there is no Magnetic Resonance Imaging (MRI) contrast agent that 
selectively targets cancer, despite it being the highest resolution diagnostic technique. 
The challenge lies with designing a biocompatible FDA- approvable contrast agent that 
can locally accumulate only in the extracellular environment of tumor tissue at a 10 µM 
concentration. To accumulate an imaging agent selectively in the tumor tissue we have 
established a new class of self-assembling vehicles that circulate through the body as 10 
nm spherical micelles and transition into slowly diffusing µm-long fibers upon entering 
the acidic extracellular vasculature of tumor tissue. However, to maximize accumulation, 
it is essential to maximize the amount of time that these vehicles circulate through the 
blood stream before they are cleared by the immune system. The addition of a 
polyethylene glycol (PEG) shell to circulating vehicles is a well-established method for 
minimizing an immune response, and allowing long circulation. However, incorporating 
this PEG shell onto these transitioning peptide amphiphile (PA) vehicles impacts their 
self-assembly behavior. Here, we have established the influence of PEG on the 
transitioning properties of these PAs through the characterization of the pH – 
concentration phase diagrams of different mixtures of 2000 kDa PEGylated and 
unPEGylated PAs. We show that PEG termination disrupts self-assembly, resulting in an 
increased critical micelle concentration and a more acidic nanofiber to micelle transition. 
PAs that have greater propensity to form nanofibers need more relative amounts of 
PEGylated PAs to maintain a transition at a uniform pH. In conclusion, we show that it is 
indeed possible to create a PEGylated vehicle that transitions in a serum environment at a 
pH of 7, which will enable the creation of a long-circulating transitioning MRI contrast 
agent.   
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Chapter 1: Introduction  
Cancer accounts for approximately 1 of every 4 deaths in the United States. 
According to the American Cancer Society, in 2017, 1,688,780 people will be diagnosed 
with cancer and 600,920 Americans will die of cancer1. The key to decreasing cancer 
mortality, according to reports by the American Cancer Society is to develop better 
methods for early detection2.  As an example, the 5-year survival rate for patients having 
localized breast cancer is 98.6%, which is reduced to 23.3% after it metastasizes3.   
Currently, most cancer is detected at later stages when symptoms are presented2. 
Developing an imaging modality that can selectively detect cancerous tissue at early 
stages with small (< 1 cm) tumor sizes will enable earlier treatments, and likely decreased 
mortality. Compared to all the imaging modalities that exist (Near Infrared Imaging, 
MRI, and Positron Emission Tomography), MRI gives the highest spatial resolution (< 1 
mm) and is noninvasive4. However, the challenge with MRI lies with the fact that a 
contrast agent that selectively accumulates in tumor tissue across a broad range of cancer 
types at an imaging concentration of  >10 µM is needed5,6.  No such MRI agent currently 
exists. 
 This research aims to develop such an imaging agent.  We seek to take advantage 
of the hallmarks common to all cancer types that are distinct from healthy tissue. One 
such hallmark of cancer is the upregulation of anaerobic glycolysis7. This results in an 
acidic microenvironment around the tumor cells due to the production of lactic acid, 
which is excreted from cancer cells7.  Typically the extracellular pH (pHe) for tumor 
tissue can range from 6.4-7.4, depending on the rate of growth7,8. A second hallmark is 
the leakiness of tumor vasculature, which can increase the rate of drug delivery to the 
tumor. The cells of the endothelial layer of the vessels are irregular and disorganized and 
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thus permit some leaking of vessel components through the walls. The leaked vessel 
components are then somewhat retained by the tumor due to poor lymphatic drainage. 
These two characteristics are known as the Enhanced Permeability and Retention (or 
EPR) effects9,10,11.   
Research in the Goldberger lab has previously taken advantage of these hallmarks 
to create nanovehicles that transition in response to the acidic microenvironment and 
accumulate at the tumor site (Figure 1)12.  The overall ideal is to develop a self-
assembling vehicle that circulates through the bloodstream as either a spherical micelle or 
small molecule at the normal blood pH of 7.4.  Once it diffuses into the acidic tumor 
vasculature, it self-assembles into a much larger, more slowly-diffusing nanofiber.  Such 
a mechanism should maximize the accumulation of vehicles in the tumor tissue, since 
diffusion is the main mechanism for which vehicles and enter and leave the tumor 
microenvironment. The challenge lies with creating vehicle that can undergo such a 
transition in vivo.   
 
Figure 1: An overview of the PA’s morphological transition when interacting with the acidic microenvironment of a 
tumor.  In this design, single molecules or spherical micelles circulate through the blood stream at a pH of 7.4, then 
diffuse into the acidic leaky vasculature of tumor tissue, allowing for a self-assembly transition into a much larger 
nanofiber morphology.    
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The Goldberger lab has established PA nanovehicles that can undergo such a pH-
dependent transition in pure blood serum12.  PAs are a class of self-assembling molecules 
comprised from biocompatible building blocks (peptides and lipids) that can be thought 
of as peptide surfactants. These molecules typically contain a hydrophobic region, a B-
sheet forming region, a charged region, and a region that chelated to an MRI contrast 
agent (Figure 2)12,13,14,15.  Typically, 1,4,7-tris(carboxymethylaza)cyclododecane-10-
azaacetylamide (DO3A) moiety is attached to at terminal lysine, which chelates the Gd3+ 
imaging agent. The surfactant-like nature of these molecules enables them to self-
assemble into spherical micelles, 1D nanofibers upon the presence of the β -sheet 
depending on the pH and concentration, and solution environment16,17. When a micelle 
forms, the hydrophobic tails arrange in the center of the micelle, allowing the charged 
regions to interact with the aqueous environment. A nanofiber forms when the attraction 
between amino acids in the β-sheet region overcome the electrostatic repulsion induced 
by the charged amino acid residues, enabling the formation of β -sheets along the length 
of the fiber.  These β-sheets consist of hydrogen bonding interactions between 
neighboring molecules.  
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Figure 2: The structure of a peptide amphiphile (PA). The PA has a hydrophobic tale, a B sheet region, which 
promotes the formation of nanofibers, a charged region, which promotes the formation of micelles, and an imaging 
region.  
 Initial in vivo biodistribution tests in tumor animals show appreciable 
accumulation in the tumor tissue, as well as the liver, lungs, and spleen, which is 
indicative of an immune system response18. The detection by the mononuclear phagocyte 
system (MPS) are reasons for the clearance of the PAs by these organs18.  One standard 
method to minimize vehicular uptake by the immune system is to add a polyethylene 
glycol (PEG) moiety to its outer surface. PEG is an FDA-approved polymer that 
commonly coats biomaterials by preventing opsonization and removal from the immune 
system19,20.  
The goal of this thesis, is to understand how the addition of different relevant 
amounts of a 2000 Da PEG  (PEG2k) moiety to the outer terminus affects the self-
assembly properties of these PAs, as well as design a formulation that can transition in a 
simulated blood serum environment at a pH of 6.6-7.0.   To accomplish this we 
synthesized and characterized the self-assembly properties of two different PAs that have 
varying amino acids in the B-sheet forming region (Table 1, Figs 3-5). Specifically, we 
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have developed two PAs that feature Valine (V) or Isoleucine (I) in the β -sheet forming 
region, (palmitoyl-VAAAEEEEK(DO3A:Gd)-NH2, and palmitoyl-
IAAAEEEEK(DO3A:Gd)-NH2, as PA1 and PA2, respectively). Then mixtures of non-
PEGylated PA with varying percentages of palmitoyl-MAAAEEEEK(PEG2k)-NH2  
(PA3PEG) were prepared and the changes in the pH- and concentration-dependent self-
assembly phase diagram were characterized. Overall, we showed that the addition of 
PA3PEG to the mixture disrupts micelle and nanofiber formation, leading to increases in 
the critical micelle concentration and more acidic nanofiber to micelle transitions. PA2, 
which features a greater propensity to form nanofibers than PA1, needs a greater 
concentration of PA3PEG to induce a micelle to nanofiber transition at pH of 721. In 
conclusion, we show that it is indeed possible to create a PEGylated vehicle that 
transitions in a simulated serum environment at a pH of 7. This work will enable future 
biodistribution studies evaluating the accumulation of these vehicles in a simulated serum 
environment.  
Table 1: A summary of the sequence of the PAs synthesized in this work.  
Molecule Sequence 
PA1 palmitoyl-VAAAEEEEK(DO3A:Gd)-NH2 
PA2 palmitoyl-IAAAEEEEK(DO3A:Gd)-NH2 
PA3PEG palmitoyl-MAAAEEEEK(PEG2k)-NH2 
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Figure 3: Structure of PA1 or PA2 
 
 
 
Figure 4: Structure of PA3PEG  
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Chapter 2: PA Synthesis  
 
All PAs were synthesized using traditional solid-phase peptide synthesis. Amino 
acids were coupled using Fluorenylmethoxycarbonyl (FMOC) chemistry from the C-
terminus to the N-terminus. Additionally, the PAs were synthesized on a 0.5-0.75 mmol 
scale using a Sieber amide resin. The resin was added to a shaker vessel with 
dichloromethane (DCM) and shaken. After 30 minutes the DCM was removed and 
dimethyl formamide (DMF) was shaken with the resin for 30 minutes. The FMOC using 
20% piperidine in DMF, which was shaken for 20 minutes twice. Afterwards, a Kaiser 
test was run to confirm that the deprotection was successful. If the test turns blue, the 
amine is primary. Then 4 equivalents of the amino acid were mixed with either 4 
equivalents of O- Benzotriazole N,N,N’,N’-tetramethyluronium hexafluoro-phosphate 
(HBTU), or 2-(7-Aza- 1H-benzotriazole-1-yl)-1,1,3,3 tetramethyluronium 
hexafluorophosphate (HATU) as coupling agents, along with 6 equivalents of N,N- 
diisopropyl-ethylamine (DIPEA), and 2 drops of Triton X-100 surfactant in 
approximately 10mL of DMF. The first amino acid coupled on the resin was lysine, 
which featured an ε-NH-methyltrityl (MTT) protecting group.  This mixture was shaken 
for at least 2 hours. Afterwards, it was rinsed with DCM and DMF. A Kaiser test was run 
again to confirm the coupling of the amino acid. If the test stays yellow, it is confirmation 
of a successful coupling yielding no free amines. This cycle is repeated to couple the 
subsequent amino acids as well as the palmitic acid chain.  
The next steps in PA synthesis involve cleaving from the resin and coupling either 
PEG2k or DO3A to the terminal lysine residue.  The PAs were cleaved from the resin 1% 
Trifluoroacetic acid (TFA), 1% Triisopropyl silane (TIS), 2% Anisole and 96% DCM.  
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This cleavage solution both cleaves the PA from the resin as well as deprotects the MTT 
protecting group attached to the terminal lysine.  After precipitating the PA out of 
solution with cold distilled water it was dried and solubilized with 15mL of pyridine 
through heating (60 ºC to couple either DO3A or PEG2k to the terminal lysine. To couple 
with DO3A, the solubilized PA was mixed at room temperature with 2 eq. HATU, 2 eq. 
DO3A, and 4.4 eq. DIPEA for 18-24 hours. A second addition of 2 eq. HATU and 4.4 eq. 
DIPEA were added to the mixture for 2 more hours. The PA was then precipitated out of 
solution with cold distilled water and dried. The solid was mixed with 95% TFA, 1% 
TIS, 2% Anisole, 2% water to remove the protecting tert-butyl groups. The PA was then 
precipitated out with cold diethyl ether and dried.  
The crude PA was purified with High Performance Liquid Chromatography 
(HPLC) using a preparative scale Shimadzu duel pump system and an Agilent PLRP-S 
polymer column. The PA was solubilized in 9 mL of distilled water and 1 mL of 
acetonitrile, basified with a couple drops of NH4OH. The solution was filtered through a 
0.45 µm PVDF filter before injection. A gradient of acetonitrile with 0.1% NH4OH was 
increased from 10% to 100% over the HPLC column to elute out the PA.  To identify 
which HPLC fractions contained the PA they were analyzed with ESI-TOF Mass 
Spectrometry. A couple drops of the fraction solution were serially diluted in 5 mL of 
methanol (MeOH). About 200 µL of the most dilute sample was injected into a Bruker 
Daltonics MicroTOF Mass Spectrometer for mass analysis.  
Fractions with significant signals corresponding to the PA mass were analyzed 
with a Shimadzu analytical HPLC dual pump system.  The purified PA was solubilized in 
distilled water and a couple drops of NH4OH was filtered with a 0.2 µm filter and 
	 14	
injected into the analytical HPLC. A gradient of acetonitrile from 10% to 100% with 
0.1% NH4OH was applied over the column to elute out the PA to test the fractions for 
purity. Fractions with at least 95% purity were combined, rotovapped and lyophilized to 
dry powder.  
Gd3+ was then chelated to the pure DO3A terminated PAs. ~10-20 mg of pure PA 
was dissolved in ~ 5 mL distilled water and 2 eq. of 0.01 M GdCl3 in 0.01 M HCl. The 
solution pH was adjusted to ~5.0 with diluted NaOH. The solution was stirred for an hour 
at 60ºC in an oil bath, readjusted to a pH ~5.0, and stirred for 12-18 hours in the heated 
oil bath. The pH was then adjusted to ~10 to precipitate the excess Gd3+. The solution 
was then passed through a 0.45 µm PVDF filter. The solution was then dialyzed to 
remove the excess salts using a Spectra/Por® Biotech Cellulose Ester dialysis membrane 
(molecular weight cut off: 500 g/mol). The dialysis water was changed every 2 hours 
over the course of 12 hours. The dialyzed solution was then lyophilized to form dry 
powder.  
 Mass Spec and Analytical HPLC were used to purify the PA samples. Figure 5, 
Figure 6, and Figure 7 show the MS-ESI of PA1, PA2, and PA3PEG respectively. The 
largest peak seen corresponds to the mass of the synthesized PA. Figure 8, Figure 9, and 
Figure 10 show the analytical HPLC to confirm purity of the PA samples.  
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Figure 5: Mass Spectrometry of PA1 M/Z=1752. 
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Figure	6:	Mass	Spec	of	PA2	M/Z=1766 
 
Figure	7:	Mass	Spec	of	PA3PEG	M/z~3020 
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Figure 8: Analytical HPLC of purified PA1 
 
	
Figure	9:	Analytical	HPLC	of	PA2	
 
min	
min	
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Figure	10:	Analytical	HPLC	of	PA3PEG 
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Chapter 3: Self-Assembly Behavior  
  
 Our next goal was to understand the influence of adding different concentrations 
of PA3PEG on the self-assembly behavior of  PA1 and PA2. The pH and concentration 
dependent self-assembly behavior was characterized for all PAs in an artificial serum 
solution that mimics the complex environment of pure blood serum.  The Goldberger lab 
previously established that an artificial serum solution containing 150 mM NaCl, 2.2 mM 
CaCl2, and 1.8 mM 20 kDa PEG effective simulates the ionic strength and molecular 
crowding environment of pure blood serum, showing very similar pH-dependent self-
assembly behavior.22 The lack of any proteins in this media allows the use of Circular 
Dichroism (CD) and critical micelle concentration measurements using the pyrene 1:3 
method to characterize the self-assembled morphology of the PA.  
The PAs were prepared for Circular Dichroism (CD) measurements on the Jasco-
815 Circular Dichroism spectrometer. PAs were prepared in this artificial serum medium 
with varying percentages of PA3PEG. The solution was basified to a pH >9 and stirred at 
90 oC for 30 minutes. After the solution was cooled, the pH was readjusted. 
Measurements were conducted in 0.5-1 cm path length quartz cuvettes. The pH of the 
solution is lowered in increments to see the pH range for which the PAs shift from 
random coil to a nanofiber assembly. Data was collected from wavelength 250-190 nm. 
A β-sheet secondary structure is defined as one with a  local minimum in the ellipiticity 
around 218 nm, and an increasing ellipticity at lower wavelengths.  A random coil 
secondary structure has a The crossing of the x-axis around 218 nm indicates a shift to a 
nanofiber assembly22. A cuvette with distilled water was run to serve as a baseline to be 
subtracted from the other measurements. 
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The Goldberger lab has previously analyzed secondary structure transitions of 10 
µM of PA2 and PA1 in a salt solution (150 mM NaCl, 2.2 mM CaCl2).23 The increased β-
sheet propensity of the isoleucine residue in PA causes it transition from random coil to 
β-sheet morphologies at a higher pH (pH=5.65) than the transition for the valine-
containing PA1 (pH = 5.27). We then collected the CD spectra of both PAs in the 
artificial serum media comprised of 150 mM NaCl, 2.2 mM CaCl2 and 1.8 mM 20 kDa 
PEG.  For both PA1 and PA2, only beta-sheet morphologies were observed from 10 µM-
500 µM at pH values ranging from 5-10, indicating no self-assembly transition occurs.     
 
Figure 11: PA1 (left) and PA2 (right) CD at different pH values at 10 µM, 150 mM NaCl, 2.2 mM CaCl2.  Figure 
taken with permission from Ref 23.23 
 
 The Critical Aggregation Concentration (CAC) is the lowest concentration at a 
given pH when the PAs will self-assemble into structures. The PAs were made into 
solutions with varying percentages of PA3PEG with 150 mM NaCl and 2.2 mM CaCl2 
with 1.8 mM PEG. The PA solutions were made between 100 nM and 700 µM with serial 
dilutions. Each concentration sample also had 6 µM of pyrene and HCl or NaOH to 
adjust the pH. The solution is then pipetted into 96-well plates and the fluorescence is 
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monitored with a hybrid reader fluorometer. When reaching higher concentrations, the 
PAs self assemble, which encapsulates the pyrene in solution. This is seen as a change in 
slope of I376/I392 when excited at 335 nm, which is what we used to determine the CAC.  
	
Figure	12:PA1	with	3.5%	PA3PEG	at	pH7	in	artificial	serum.	CAC	value	determined	to	be	30.5	μM. 
 Transmission Electron Microscopy (TEM) images were collected to visualize the 
PAs self-assembly at different pH values and concentrations. They were obtained with a 
FEI Tecnai G2 Bio TWIN TEM system. The samples were prepared for TEM in 150 mM 
NaCl, 2.2 mM CaCl2, at 100 µM PA in 1.5% artificial serum. The samples without serum 
were heated and all samples had pH adjustments using HCl or NaOH. The samples were 
then carefully pipetted on Carbon Formvar grid, allowed to sit for a minute, and then the 
excess liquid was carefully removed with filter paper. The samples on the grid were 
stained with 1 wt% uranyl acetate.  
 CD and CAC data compiled generated phase diagrams, which are able to show at 
what pH and concentrations the PA mixtures will self assemble. The CMC’s on the 
diagrams are represented by the horizontal lines at fixed pH values. They indicate the 
threshold concentration at which the PAs self assemble into either micelles or nanofibers. 
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The CD data on the graph is seen as the vertical/diagonal lines at fixed concentrations. 
They indicate the pH at which a micelle will transition to a nanofiber.  
 Figure 13 shows the phase diagram of C16VA3E4K(DO3A:Gd)-NH2 with 3.5%, 
4%, and 5% C16MA3E3K(PEG2k)-NH2 prepared in artificial serum. The CAC values 
increase as PA3PEG % increases. This shows that a higher PA3PEG% in solution 
disrupts the self-assembly of the PAs. The solution needs to have a higher PA 
concentration for to initiate self-assembly at the same pH if the PA3PEG concentration is 
higher. Figure 13 also shows the pH of transition from micelle assembly to nanofiber 
assembly. Here, the graph shows that the 4% PA3PEG mixture has a higher pH of 
transition than the 3.5% PA3PEG mixture. This means it takes a lower pH for the 3.5% 
PA3PEG mixture to transition than the 4% PA3PEG mixture. This is true too for the 4% 
PA3PEG mixture in relation to the 5% PA3PEG mixture.  
 
Table 2: CAC data from varying PA3PEG concentrations with PA1 in artificial serum. 
pH  5% 4% 3.5% 
9 88.8µM 47.1µM 16.2µM 
7 100.8µM 73.0µM 30.5µM 
5.5 114.5µM 80.5µM 47.4µM 
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Table 3: Nanofiber-micelle transition pH determined from CD data at overall PA concentrations (of 100 µM, 300 µM, 
and 500 µM) in artificial serum, different formulations varying PA3PEG concentrations with PA1 in artificial serum.    
%PA3PEG 
In PA1 
500µM 300µM 100uM 
5% 7.79 6.45 6.34 
4% 7.87 6.67 6.56 
3.5% 7.89 6.63 6.65 
 
 
Figure 13: Phase diagram complied from CD (diamonds) and CAC (spheres) data of varying concentrations of 
PA3PEG in relation to PA1 in artificial serum.  
 
TEM images of C16VA3E4KDO3A:Gd were taken in various acidic and 
concentrated solutions that caused the PAs to assemble as nanofibers as predicted by the 
CD and CMC. The images confirmed the presence of fibers in the PA3PEG mixture 
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under acidic (pH=5.5) and concentrated (300 µM) conditions. The average diameter of 
the fibers was about 12 nm, which is in line with expected nanofiber diameters.  
 
Figure 14: TEM images with a 100nm scale bar confirming nanofiber morphology of PA1 with 3.5% PA3PEG under 
acidic and high concentration conditions. Fibers are measured to be 12nm in diameter.  
Figure 15 shows the phase diagram of C16IA3E4K(DO3A:Gd)-NH2 with 11%, and 
13% C16MA3E3K(PEG2k)-NH2 prepared in artificial serum. The CAC values increase as 
PA3PEG % increases. This shows that a higher PA3PEG% in solution disrupts the self-
assembly of the PAs. The solution needs to have a higher PA concentration for to initiate 
self-assembly at the same pH if the PA3PEG concentration is higher. Figure 15 also 
shows the pH of transition from micelle assembly to nanofiber assembly. Here, the graph 
shows that the 11% PA3PEG mixture has a higher pH of transition than the 13% 
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PA3PEG mixture. This means it takes a lower pH for the 11% PA3PEG mixture to 
transition than the 13% PA3PEG mixture.  
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Table 4: Random coil –self-assembled transition concentration determined from CAC data at pH’s of 5.5,7, and 9 in 
artificial serum at varying PA3PEG concentrations with PA2. 
 
pH 13% 11% 
9 117.6 µM 35 µM 
7 112.3 µM 52.3 µM 
5.5 107.7 µM 16.3 µM 
 
 
 
Table 5. Nanofiber-micelle transition pH determined from CD data at overall PA concentrations (of 100 µM, 300 µM, 
and 500 µM) in artificial serum, different formulations varying PA3PEG concentrations with PA2. 
 500µM 300µM 100µM 
13% 7.68 6.98 6.58 
11% 8.04 7.54 6.72 
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Figure 15:  Phase diagram complied from CD and CAC data of varying concentrations of PA3PEG in relation to PA2 
in artificial serum.  
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Chapter 4: Conclusion and Future Work 
The characterization of the effects of PEGylation has revealed that its 
incorporation can affect self assembly. CD analysis found that an increase in PA3PEG 
concentration disrupts self assembly. More PA3PEG disrupts the ability of the micelle to 
transform into a nanofiber. Understanding how PEG changes assembly behavior is 
important because the vehicles that deliver the MRI contrast agent need to be fine-tuned 
to transition upon the slightly lower pH (6.4-7.2) of the microenvironment of the cancer 
cells compared to that of the blood pH (7.4).  
The CAC studies found that an increase in PA3PEG concentration disrupts self 
assembly. A higher percentage of PA3PEG at a given pH increases the concentration of 
PA needed to allow for self-assembly into micelles or nanofibers. Understanding how 
PEG incorporation affects the transitioning concentration is important because the 
nanovehicle has to aggregate at concentration that is at least the concentration of Gd3+ 
needed to effectively image with MRI (10 µM).  
 A comparison of the phase diagrams of C16VA3E4KDO3A:Gd and 
C16IA3E4KDO3A:Gd both with PA3PEG gives information about how β -sheet 
propensity affects the amount of PA3PEG needed for a transition near pH 7. PAs that 
have greater propensity to form nanofibers, for example C16-IA3E4KDO3A:Gd, need 
more relative amounts of PEGylated PA’s to maintain a transition at a uniform pH.  
CMC, CD, and TEM data offers information about how PEG incorporation 
affects the self assembly behavior of the synthesized PAs. Future research will also entail 
performing mouse experiments to confirm the biocompatibility of the PAs. Experiments 
in true serum are a necessary step to come closer to having the PA system become FDA 
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approvable. This research will find how the PAs accumulate in the body and how long 
they circulate before being targeted by phagocytes or by being eliminated by the body.  
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